More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the Company is scheduled to present new data on its allogeneic CRISPR-based CAR-T programs at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 16, 2018 in Chicago, IL.
Presentation: Allogeneic chimeric antigen receptor T cells targeting B cell maturation antigen
Session: Adoptive Cell Therapy 1
Time and Date: 8:00 AM – 12:00 PM CDT, Monday, April 16, 2018
Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 1540
Presentation: Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells
Session: Adoptive Cell Therapy 2
Time and Date: 1:00 PM - 5:00 PM CDT, Monday, April 16, 2018
Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 2551
Following presentation at the meeting, the posters will be available on CRISPR Therapeutics’ website at http://www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
CONTACTS
CRISPR Therapeutics
Investors:
Chris Erdman
617-307-7227
[email protected]
or
Chris Brinzey
Westwicke Partners
339-970-2843
[email protected]
Media:
Jennifer Paganelli
WCG for CRISPR
347-658-8290
[email protected]
